The FDA has granted ENHERTU® Breakthrough Therapy Designation in the US for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.
[FDA (BusinessWire, Inc.)]
6445218
{6445218:AAAAAAAA}
apa
50
1
167501
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
